Re­play part­ners with MD An­der­son’s Katy Rez­vani, heads to clin­ic with new TCR NK cell com­pa­ny

Hub-and-spoke com­pa­ny Re­play has launched a new cell ther­a­py com­pa­ny called Sye­na, co-found­ed by NK cell leader Katy Rez­vani of the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter.

Sye­na plans to put Rez­vani’s T cell re­cep­tor nat­ur­al killer, or TCR NK, cell ther­a­pies in­to a Phase I tri­al in the sec­ond quar­ter of the year. That would make it the first to bring a TCR NK cell ther­a­py in­to the clin­ic, Rez­vani told End­points News. Rez­vani added that they’re work­ing on an IND pack­age to sub­mit to the FDA, which should hap­pen “in the next cou­ple of weeks or so.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER